HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NMS P937

a polo-like kinase 1 inhibitor; structure in first source

Also Known As:

NMS-P937

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - NMS P937: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - NMS P937: 5

Experts

1.	Valsasina, Barbara: 2 articles (12/2014 - 04/2012)
2.	Croce, Carlo M: 1 article (01/2022)
3.	Distefano, Rosario: 1 article (01/2022)
4.	Gasparini, Pierluigi: 1 article (01/2022)
5.	Kudo, Masahisa: 1 article (01/2022)
6.	Nigita, Giovanni: 1 article (01/2022)
7.	Veneziano, Dario: 1 article (01/2022)
8.	Zalles, Nicole: 1 article (01/2022)
9.	Fanelli, Marilù: 1 article (12/2014)
10.	Gudeman, Beth: 1 article (12/2014)

Related Diseases

1.	Neoplasms (Cancer) 04/01/2012 - "NMS-P937 potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits xenograft tumor growth with clear PLK1-related mechanism of action at well-tolerated doses in mice after oral administration. " 10/15/2023 - "Co-treatment with VS-5584 and PLK1 inhibitor NMS-P937 resulted in enhanced cancer cell death, exhibiting synergistic inhibitory activity. " 12/01/2014 - "Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance." 11/30/2023 - "Polo-like kinase 1 (PLK1) inhibitor NMS-P937 is a targeted therapeutic agent with good preclinical efficacy in various human cancers, and its therapeutic effect on nasopharyngeal carcinoma (NPC) remains to be determined. " 04/01/2012 - "In addition, NMS-P937 shows potential for combination in clinical settings with approved cytotoxic drugs, causing tumor regression in HT29 human colon adenocarcinoma xenografts upon combination with irinotecan and prolonged survival of animals in a disseminated model of acute myelogenous leukemia in combination with cytarabine. "
2.	Hematologic Neoplasms (Hematological Malignancy) 04/01/2012 - "NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies."
3.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/01/2012 - "In addition, NMS-P937 shows potential for combination in clinical settings with approved cytotoxic drugs, causing tumor regression in HT29 human colon adenocarcinoma xenografts upon combination with irinotecan and prolonged survival of animals in a disseminated model of acute myelogenous leukemia in combination with cytarabine. "
4.	Osteosarcoma (Osteogenic Sarcoma) 12/01/2014 - "Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance."
5.	Colonic Neoplasms (Colon Cancer) 04/01/2012 - "In addition, NMS-P937 shows potential for combination in clinical settings with approved cytotoxic drugs, causing tumor regression in HT29 human colon adenocarcinoma xenografts upon combination with irinotecan and prolonged survival of animals in a disseminated model of acute myelogenous leukemia in combination with cytarabine. "

Related Drugs and Biologics

1.	Polo-Like Kinase 1
2.	Therapeutic Uses
3.	MicroRNAs (MicroRNA)
4.	Cytarabine (Cytosar-U)
5.	Irinotecan (Camptosar)
6.	VS-5584

Related Therapies and Procedures

1.	Oral Administration